Cardiac complications in childhood cancer survivors treated with anthracyclines

Cardiology in the Young

Volumn 25, Issue S2, 2015, Pages 107-116

  Franco, Vivian I ^a   Lipshultz, Steven E ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Anthracyclines; cardiotoxicity; childhood cancer survivors; dexrazoxane

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; DOXORUBICIN; ENALAPRIL; RAZOXANE; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; BLACK PERSON; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CBR3 GENE; CHILDHOOD CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; GENE; GENE FREQUENCY; GENE MUTATION; HEART DISEASE; HEART FAILURE; HEART MUSCLE INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; LOW DRUG DOSE; PATHOGENESIS; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; NEOPLASMS; PEDIATRICS; SURVIVOR;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; DEXRAZOXANE; HEART FAILURE; HUMANS; NEOPLASMS; PEDIATRICS; RISK FACTORS; SURVIVORS;

EID: 84941911080     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951115000906     Document Type: Conference Paper

References (62)

1. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315
2. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008; 100: 1368-1379
3. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83-103
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582
5. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31: 3673-3680
6. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606
7. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014; 32: 1218-1227
8. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815
9. Diamond MB, Franco VI, Miller TL, et al. Preventing and treating anthracycline-related cardiotoxicity in survivors of childhood cancer. Curr Cancer Ther Rev 2012; 8: 141-151
10. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?. Prog Cardiovasc Dis 2010; 53: 105-113
11. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639-1642
12. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-2636
13. Minow R, Benjamin R, Gottlieb J. Adriamycin (NSC-123127) cardiomyopathy-overview with determination of risk-factors. Cancer Chemother Rep 1975; 6: 195-201
14. Lipshultz SE, Scully RE, Stevenson KE, et al. Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. J Clin Oncol 2014; 32: 10021, (abstract
15. Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 2000; 12: 1-28
16. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533
17. Van Der Pal HJ, Van Dalen EC, Van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30: 1429-1437
18. Kremer LC, Van Dalen EC, Offringa M, et al. Anthracyclineinduced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191-196
19. Orgel E, Zung L, Ji L, et al. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer 2013; 60: 1528-1533
20. Leger K, Slone T, Lemler M, et al. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer 2015; 62: 123-127
21. Bansal N, Franco VI, Lipshultz SE. Anthracycline cardiotoxicity in survivors of childhood cancer: clinical course, protection, and treatment. Progr Pediatr Cardiol 2014; 36: 11-18
22. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743
23. Landy DC, Miller TL, Lipsitz SR, et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatr Cardiol 2013; 34: 826-834
24. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012; 120: 4505-4512
25. Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012; 30: 1050-1057
26. Sterba M, Popelova O, Vavrova A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013; 18: 899-8929
27. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-171
28. Hasinoff BB, Kuschak TI, Yalowich JC, et al. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).Biochem Pharmacol 1995; 50: 953-958
29. Herman EH, Hasinoff BB, Steiner R, et al. A review of the preclinical development of dexrazoxane. Progr Pediatr Cardiol 2014; 36: 33-38
30. Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol 2012; 13: 1949-1956
31. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153
32. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950-961
33. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25: 493-500
34. Lipshultz SE, Franco VI, Sallan SE, et al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Progr Pediatr Cardiol 2014; 36: 39-49
35. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-828
36. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517-4522
37. Levitt GA, Dorup I, Sorensen K, et al. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Haematol 2004; 124: 463-468
38. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139
39. Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 2012; 130: 1003-1011
40. Gupta M, Steinherz PG, Cheung NK, et al. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003; 40: 343-347
41. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20: 1677-1682
42. Colan SD, Lipshultz SE, Sallan SE. Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer. Progr Pediatr Cardiol 2014; 36: 7-10
43. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-2648
44. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with highrisk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30: 1042-1049
45. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J Clin Oncol 2012; 30: 1415-1421
46. Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013; 119: 3555-3562
47. Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med 2015; 66: 161-176
48. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-372
49. Paiva MG, Petrilli AS, Moises VA, et al. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using lowdose dobutamine stress echocardiography. Pediatr Blood Cancer 2005; 45: 902-908
50. De Matos Neto RP, Petrilli AS, Silva CM, et al. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. Arq Bras Cardiol 2006; 87: 763-771
51. Choi HS, Park ES, Kang HJ, et al. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J Korean Med Sci 2010; 25: 1336-1342
52. Kang M, Kim KI, Song YC, et al. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients. J Chemother 2012; 24: 292-296
53. Asselin BL, Devidas M, Zhou T, et al. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J Clin Oncol 2012; 30: 9504, (abstract
54. Kopp LM, Bernstein ML, Schwartz CL, et al. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). J Clin Oncol 2012; 30: 94877, (abstract
55. Shaikh F, Alexander S, Dupuis L, et al. Cardiotoxicity and second malignant neoplasms associated with dexrazoxane in children and adolescents: a systematic review of randomized trials and nonrandomized studies. J Clin Oncol 2014; 32: 10093, (abstract
56. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26: 1106-1111
57. Schwartz CL, Constine LS, Villaluna D, et al. A risk-Adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114: 2051-2059
58. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 2010; 24: 355-370
59. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47: 1373-1379
60. Tebbi CK, Mendenhall NP, London WB, et al. Responsedependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59: 1259-1265
61. Seif AE, Walker DM, Li Y, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 2015; 62: 704-709
62. Chow EJ, Asselin B, Schwartz CL, et al. Late mortality and relapse after dexrazoxane (DRZ) treatment: an update from the Children's Oncology Group (COG). J Clin Oncol 2014; 32: 10024 (abstract